Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › abrocitinib

abrocitinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of abrocitinib

2 trials tracked of abrocitinib.

2Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 1 Phase 1 1
  1. Phase 2 Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Completed
  2. Phase 1 A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Abrocitinib significantly improves Investigator Global Assessment response and pruritus in moderate-to-severe atopic dermatitis
Drug Pipeline Meta-analysis
Abrocitinib significantly improves Investigator Global Assessment response and pruritus in moderate-to-severe atopic dermatitis Abrocitinib improves skin severity and itching in eczema patients
This meta-analysis of randomized controlled trials evaluated abrocitinib for patients with moderate-to-severe atopic dermatitis. The analysi…
A new analysis shows abrocitinib helps people with moderate to severe atopic dermatitis reduce skin inflammation and experience less intense…
Frontiers Aug 24, 2026
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis
Dermatology Sys. Review
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis Upadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis
A systematic review and network meta-analysis of 9 RCTs (4261 adults) found upadacitinib 30 mg had the highest efficacy for EASI-75, IGA-AD …
A review of data from over 4,000 patients suggests upadacitinib may be the most effective oral treatment among several JAK inhibitors for se…
Jul 1, 2026